Compare FRD & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRD | STTK |
|---|---|---|
| Founded | 1965 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.3M | 119.0M |
| IPO Year | N/A | 2020 |
| Metric | FRD | STTK |
|---|---|---|
| Price | $19.52 | $3.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 23.0K | ★ 224.7K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | ★ 43.48 | N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | ★ $510,450,000.00 | $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.97 | ★ N/A |
| Revenue Growth | ★ 8.72 | N/A |
| 52 Week Low | $12.24 | $0.69 |
| 52 Week High | $23.50 | $3.12 |
| Indicator | FRD | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 44.85 | 79.66 |
| Support Level | $18.46 | $1.93 |
| Resistance Level | $19.99 | $2.18 |
| Average True Range (ATR) | 1.10 | 0.20 |
| MACD | -0.09 | 0.12 |
| Stochastic Oscillator | 24.17 | 98.42 |
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.